Users average 10-20% body weight reduction over 6 months, with women often reporting faster mental well-being gains
In the vast majority of cases, yes
In the future, Retatrutide may be considered for individuals who meet specific health criteria, such as those living with obesity or weight-related conditions, but suitability would depend on personal medical factors
B., Lathigara, D
During his endocrinology training in Melbourne, he won the top registrar award at the Endocrine Society of Australia Clinical Weekend in 2016, followed by securing Australia's only Andrology fellowship in 2017
2) Glycaemic control endpoints in type 2 diabetes research protocols Retatrutide has also been evaluated in a phase 2 type 2 diabetes trial (The Lancet) that measured: HbA1c change at 24 weeks body weight change at 24 weeks adverse events and discontinuations within the protocol The paper reports dose dependent improvements in both glycaemic and weight outcomes in the trial setting, which is why retatrutide is often discussed as a next generation metabolic peptide for integrated glycaemic and weight endpoints in published clinical research